Valneva SE (VALN) Interest & Investment Income (2021 - 2026)
Valneva SE (VALN) posted quarterly Interest & Investment Income of $598563.9 for Q1 2026, up 2.94% year-on-year from $581494.6 in Q1 2025, and up 175.14% on a QoQ basis from -$796568.0 in Q4 2025.
Valneva SE (VALN) Interest & Investment Income (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Interest & Investment Income for 6 consecutive years, with $598563.9 the latest figure, recorded in Q1 2026.
- Quarterly Interest & Investment Income rose 2.94% year-over-year to $598563.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 19.95% YoY) and the FY2025 annual result came in at -$3.0 million, down 8.33% from the prior year.
- Interest & Investment Income climbed to $598563.9 in Q1 2026 per VALN's latest filing, from -$796568.0 in the prior quarter.
- Over the last five years, Interest & Investment Income for VALN reached as high as $630426.7 in Q2 2025 and fell as low as -$3.4 million in Q3 2025.
- A 5-year average of -$201083.2 and a median of $250349.9 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income jumped 2133.33% — and 2024, when it slumped 1048.64%.
- Year by year, Interest & Investment Income stood at $228728.8 in 2022, then surged by 141.79% to $553045.8 in 2023, then sank by 326.34% to -$1.3 million in 2024, then jumped by 36.36% to -$796568.0 in 2025, then soared by 175.14% to $598563.9 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $598563.9, -$796568.0, and -$3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Valneva SE | 839.21 Mn | 719.43 Mn | 5.38 Mn | 598,563.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 598,563.95 |
| Dec 31, 2025 | -796,567.99 |
| Sep 30, 2025 | -3.37 Mn |
| Jun 30, 2025 | 630,426.67 |
| Mar 31, 2025 | 581,494.63 |
| Dec 31, 2024 | -1.25 Mn |
| Sep 30, 2024 | -2.37 Mn |
| Jun 30, 2024 | 592,874.18 |
| Mar 31, 2024 | 302,695.84 |
| Dec 31, 2023 | 553,045.78 |
| Sep 30, 2023 | 250,349.94 |
| Jun 30, 2023 | 285,626.52 |
| Mar 31, 2023 | 287,902.43 |
| Dec 31, 2022 | 228,728.81 |
| Sep 30, 2022 | 27,310.90 |
| Jun 30, 2022 | 25,034.99 |
| Mar 31, 2022 | 14,793.41 |
| Dec 31, 2021 | 10,241.59 |
| Sep 30, 2021 | 13,655.45 |
| Jun 30, 2021 | -8.50 Mn |